Final answer:
In the EMPA-REG Outcomes Trial, a Major Adverse Cardiac Event refers to cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This trial evaluated the effects of empagliflozin on cardiovascular outcomes in people with type 2 diabetes.
Step-by-step explanation:
In the EMPA-REG Outcomes Trial, a Major Adverse Cardiac Event (MACE) referred to a specific set of events related to the heart or blood vessels. These events included cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke. The EMPA-REG Outcomes Trial focused on evaluating the effects of empagliflozin, a medication used to treat type 2 diabetes, on cardiovascular outcomes.
An example of a Major Adverse Cardiac Event would be if a participant in the trial experienced a fatal heart attack or a non-fatal stroke while taking empagliflozin.